Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21737952 | 1.00 | MAP3K12 (0.36) | MAP3K12GLSHTR1DENPP2LTA4H | |
| SCHEMBL21738004 | 0.82 | PARP1 (0.44) | — | |
| SCHEMBL21737995 | 0.82 | PARP1 (0.44) | — | |
| SCHEMBL25858352 | 0.74 | POLB (0.30) | — | |
| SCHEMBL21738242 | 0.74 | GLS (0.36) | GLS | |
| SCHEMBL25858379 | 0.74 | CHRNB2 (0.36) | GLS | |
| SCHEMBL21423871 | 0.72 | ATM (0.45) | MAP3K12LTA4H | |
| SCHEMBL21424276 | 0.72 | ATM (0.45) | MAP3K12LTA4H | |
| SCHEMBL21738024 | 0.70 | GLS (0.32) | GLSHTR1D | |
| SCHEMBL25858337 | 0.70 | GLS (0.32) | GLSHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | MAP3K12 83/4885GLS 2423/4885HTR1D 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.